Quickly uncover the breadth and depth of the editorial offerings found only in MedTech Strategist and Market Pathways – the medtech industry’s leading sources of global business, regulatory, and reimbursement analysis and intelligence on an all-in-one, digital platform. Think Strategically. Subscribe Today
In this week’s Pathways Picks: A look at FDA’s draft MDUFA VI user fee commitment letter published this week; takeaways from CMS’s outpatient and home health payment proposals; the European Parliament weighs in on EU regulatory reform proposals; pending German bill could pressure a popular payment pathway; and more global medtech policy updates.
Each month we survey selected private financings across medtech. Urology emerged as an unexpected standout this month.
Medicare’s phased-in elimination of the inpatient only rule and simultaneous expansion of the list of procedures it covers in ambulatory surgery centers are forcing medical device manufacturers to rethink where and how much they get paid.